Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children

한국 소아에서 7가 폐렴사슬알균 단백결합 백신의 추가접종 면역원성에 관한 연구

  • Park, So Eun (Department of Pediatrics, College of Medicine, Pochon CHA University) ;
  • Lee, Hyunju (Department of Pediatrics, School of Medicine, Ewha Womans University) ;
  • Lim, Soo Young (Center for Vaccine Evaluation and Study, Ewha Medical Research Institute) ;
  • Kim, Kyung Hyo (Department of Pediatrics, School of Medicine, Ewha Womans University)
  • 박소은 (포천중문의과대학 소아과학교실) ;
  • 이현주 (이화여자대학교 의과대학 소아과학교실) ;
  • 임수영 (이화여자대학교 의과대학 의과학연구소 백신효능 연구센터) ;
  • 김경효 (이화여자대학교 의과대학 소아과학교실)
  • Received : 2008.04.21
  • Accepted : 2008.05.21
  • Published : 2008.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to evaluate the immunogenicity of the booster immunization with pneumococcal conjugate vaccine in Korean children. Methods : Thirty-nine children aged 12-23 months who visited Kangnam CHA Hospital between September 2006 and December 2006 were enrolled. The children were divided into primary and booster groups depending on their vaccination status for the 7-valent pneumococcal conjugate vaccine. The anti-pneumococcal antibody levels of each serotype included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 23F) were determined by third-generation ELISA. Results : The geometric mean titer (GMT) of antibodies to each pneumococcal serotype in the booster group was higher than in the primary group (P<.05). The percentage of subjects with pneumococcal antibodies ${\geq}0.35{\mu}g/mL$ was 90.5-100% for all serotypes in both the primary and booster groups. The percentage of subjects with pneumococcal antibodies ${\geq}1.0g/mL$ in the booster group was 94.4-100%, which was higher than the primary group except for serotypes 6B and 14 (P<.05). The percentage of subjects with pneumococcal antibodies ${\geq}5.0{\mu}g/mL$ in the booster group was 50.0-94.4% which was higher than the primary group for all serotypes (P<0.05). Conclusion : The immunogenicity of a booster dose of the pneumococcal conjugate vaccine in Korean children was high and the immunogenicity of a primary series was also relatively high. To determine the feasibility of the introduction of the pneumococcal conjugate vaccine and the appropriate schedule for Korean children, further prospective investigation of the immunogenicity of the booster immunization is needed.

목 적 : 본 연구는 우리나라 소아에서 면역원성에 근거한 추가접종의 필요성 여부를 확인하고자 하였다. 방 법 : 2006년 9월부터 2006년 12월까지 강남 차병원에 내원하여 검사를 위해 혈액 채취의 기회가 있었던 12-23개월 사이의 소아 39명을 대상으로 하였다. 7가 폐렴사슬알균 단백결합 백신의 접종력에 따라 기초접종 군과 추가접종 군으로 나누었다. 백신에 포함된 혈청형(4, 6B, 9V, 14, 18C, 19F, 23F)에 대하여 각각의 폐렴사슬알균 피막다당질 항체를 3세대 효소면역측정법으로 측정하였다. 결 과 : 각 혈청형에 대한 폐렴사슬알균 피막다당질 항체의 기하평균은 기초접종만 완료한 군보다 추가접종을 완료한 군에서 높았다(P<0.05). 폐렴사슬알균 피막다당질 항체가가 $0.35{\mu}g/mL$ 이상인 비율은 기초접종과 추가접종 군 모두에서 90.5-100%였다. 폐렴사슬알균 피막다당질 항체가가 $1.0{\mu}g/mL$ 이상인 비율은 추가접종 군에서 94.4-100%로 혈청형 6B와 14를 제외하고는 기초접종 군 보다 높았다(P<0.05). 폐렴사슬알균 피막다당질 항체가가 $5.0{\mu}g/mL$ 이상인 비율은 추가접종 군에서 50.0-94.4%로 모든 혈청형에서 기초접종 군 보다 높았다(P<0.05). 결 론 : 우리나라 소아에서 추가접종 후의 면역원성은 매우 좋았고 기초접종 이후에도 비교적 좋음을 알 수 있었다. 우리나라에 폐렴사슬알균 단백결합 백신의 도입과 접종 횟수를 결정하기 위해서는 전향적인 면역원성 연구가 지속되어야 할 것이라 생각된다.

Keywords

References

  1. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide- diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6 https://doi.org/10.1097/00006454-199803000-00008
  2. Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J. Dose dependency of antibody response in infants and children to pneuococcal polysaccharides conjugated to tetanus toxoid. Vaccine 1999;17:2726-32 https://doi.org/10.1016/S0264-410X(99)00048-1
  3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95 https://doi.org/10.1097/00006454-200003000-00003
  4. Miernyk KM, Parkinson AJ, Rudolph KM, Petersen KM, Bulkow LR, Greenberg DP, et al. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin Infect Dis 2000;31:34-41 https://doi.org/10.1086/313907
  5. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8 https://doi.org/10.1016/S0140-6736(06)68304-9
  6. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21 https://doi.org/10.1086/313608
  7. Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakok K, et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type btetanus toxoid conjugate (PRP-T) and diphtheria-tetanusacellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 1999;17:875-86 https://doi.org/10.1016/S0264-410X(98)00273-4
  8. Puumalainen T, Dagan R, Wuorimaa T, Zeta-Capeding R, Lucero M, Ollgren J, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003;22:141-9
  9. Kim NH, Lee J, Lee SJ, Lee H, Kim KH, Park SE, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine 2007;25:7858-65 https://doi.org/10.1016/j.vaccine.2007.08.022
  10. WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 2005;927:1-29
  11. Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21:3265-72 https://doi.org/10.1016/S0264-410X(03)00230-5
  12. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25:3816-26 https://doi.org/10.1016/j.vaccine.2007.01.119
  13. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 2005;192:387-93 https://doi.org/10.1086/431524
  14. Ekstrom N, Ahman H, Verho J, Jokinen J, Vakevainen M, Kilpi T, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005;73:369-77 https://doi.org/10.1128/IAI.73.1.369-377.2005
  15. Shao PL, Lu CY, Chang LY, Huang FY, Lee CY, Hsueh PR, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in Taiwanese toddlers. J Formos Med Assoc 2006;105:542-9 https://doi.org/10.1016/S0929-6646(09)60148-0
  16. Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998;101:604-11 https://doi.org/10.1542/peds.101.4.604
  17. Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anticapsular IgG concentration. J Infect Dis 2000;182:1553-6 https://doi.org/10.1086/315870
  18. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20: 25-33 https://doi.org/10.1097/00006454-200101000-00006
  19. O'Brien KL, Moisi J, Moulton LH, Madore D, Eick A, Reid R, et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 2007;196:104-14 https://doi.org/10.1086/518438
  20. Golaz A, Hardy IR, Glushkevich TG, Areytchiuk EK, Deforest A, Strebel P, et al. Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions. J Infect Dis 2000;181 Suppl 1:S203-7 https://doi.org/10.1086/315183
  21. Banatvala J, Van Damme P, Van Hattum J. Boosters for hepatitis B. European Consensus Group on Hepatitis B Immunity. Lancet 2000;356:337-8
  22. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005;11:S54-62 https://doi.org/10.1038/nm1216
  23. Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 2007; 25:1962-8 https://doi.org/10.1016/j.vaccine.2006.12.008
  24. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007;25:2518-27 https://doi.org/10.1016/j.vaccine.2006.09.029

Cited by

  1. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children vol.13, pp.None, 2008, https://doi.org/10.1186/1471-2334-13-474